ASH News Daily - Saturday, December 10, 2011 - (Page B-25)

21.5” IN MULTIPLE MYELOMA ZOMETA helps reduce and delay SREs in patients with multiple myeloma • In a stratified, randomized trial of patients with multiple myeloma and breast cancer, the percentage of patients with an SRE was consistently lower with ZOMETA vs pamidronate1 • In the multiple myeloma population, the median time to first SRE was 380 days for ZOMETA vs 286 days for pamidronate—a 3.2-month absolute difference1 Early treatment with ZOMETA may reduce risk of SREs 46% Reduction in the incidence of any SRE with early ZOMETA treatment vs delayed treatment2 Patients with multiple myeloma may be at high risk for SREs at initial diagnosis.3 Why wait to start protecting them from bone complications? • Results from a retrospective study of data (N=312) collected from physician-administered medical charts of U.S. patients with a confirmed diagnosis of symptomatic multiple myeloma which compared early treatment with ZOMETA (≤60 days after diagnosis) and delayed treatment with ZOMETA (>60 days after diagnosis)2 Highlights from the Important Safety Information • ZOMETA is contraindicated in patients with hypersensitivity to zoledronic acid or any components of ZOMETA. Hypersensitivity reactions, including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock, have been reported • Patients being treated with ZOMETA should not be treated with Reclast® (zoledronic acid) as they contain the same active ingredient • Monitor serum creatinine before each dose SRE=skeletal-related event. F:10.75” 

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com